Varex Announces Partial Redemption of Senior Secured Notes
Varex Imaging Corporation (Nasdaq: VREX) announced a partial redemption of $27 million in its 7.875% senior secured notes due 2027, totaling 10% of the outstanding principal.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
“Our continued cash generation is enabling us to further pay down our senior secured debt, and this partial redemption will reduce our on-going cash interest expense by
About Varex
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements concerning the announced partial note redemption; and any statements using the terms “believe,” “expect,” “intend,” “future,” “anticipate,” “will,” “could,” or similar statements are forward-looking statements that involve risks and uncertainties that could cause Varex’s actual results to differ materially from those anticipated. While forward-looking statements are based on assumptions and analyses made by us that we believe to be reasonable under the circumstances, whether actual results and developments will meet our expectations and predictions depend on a number of risks and uncertainties which could cause our actual results, performance, and financial condition to differ materially from our expectations. Such risks and uncertainties include global political and economic conditions, events, and hostilities; Varex’s ability to maintain compliance with our financial covenants; the continued impact of tariffs or a global trade war on Varex’s products and customer purchasing patterns; demand for and delays in delivery of products of Varex or its customers; Varex’s ability to develop, commercialize and deploy new products; the impact of reduced or limited demand by purchasers of certain X-ray products; the impact of competitive products and pricing; and the other risks listed from time to time in our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220307005284/en/
Director of Investor Relations
801.973.1566 | christopher.belfiore@vareximaging.com
Source: